Overview A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea Status: Completed Trial end date: 2019-05-31 Target enrollment: Participant gender: Summary To assess the efficacy and safety of S5G4T-1 compared to S5G4T-1 Vehicle when applied once daily for 12 weeks in patients with papulopustular rosacea Phase: Phase 3 Details Lead Sponsor: Sol-Gel Technologies, Ltd.